Organogenesis Buyback Of Apligraf Rights Could Create Acquisition Target
This article was originally published in The Gray Sheet
Executive Summary
Organogenesis is seeking to raise $20-40 mil. to repurchase worldwide marketing rights to its Apligraf bi-layered skin substitute from Novartis and avoid a bankruptcy filing by year-end